BTK inhibitors work by suppressing Bruton’s tyrosine kinase, an enzyme that transmits signals essential for the growth, survival and activation of B cells. Because mantle cell lymphoma and several other B-cell malignancies depend heavily on these signaling pathways, drugs that inhibit BTK can produce powerful clinical responses. Yet the benefit is often temporary. Many patients relapse after one or two years as lymphoma cells acquire or select for biological changes that allow them to survive despite continued treatment.

The new study, published in Nature Communications, identifies an unexpected mechanism behind this resistance. In mantle cell lymphoma cells that remain sensitive to BTK inhibitors, treatment triggers ferroptosis rather than simply starving the cells of growth signals. Ferroptosis is a distinct form of regulated cell death driven by the uncontrolled oxidation of lipids, the fatty molecules that form cellular membranes. As oxidized lipids accumulate, the membrane loses its integrity and eventually ruptures, killing the cell.

This process depends on the presence of both reactive oxygen species and available iron. Iron can catalyze chemical reactions that convert relatively stable oxygen-containing molecules into highly reactive compounds. These reactions initiate a chain reaction in membrane lipids, producing toxic lipid peroxides. Healthy cells normally prevent this damage through antioxidant systems, but rapidly dividing cancer cells operate under substantial metabolic stress and can become especially vulnerable when those defenses are disrupted.

Dr. Soo-Yeon Hwang, a postdoctoral associate in the laboratory of Dr. Jihye Paik at Weill Cornell Medicine, and colleagues compared lymphoma cells obtained from patients who responded to BTK inhibitors with cells from patients whose cancers had become resistant. The distinction was striking. BTK treatment induced the molecular and biochemical features of ferroptosis in sensitive cells, while resistant cells avoided the same fate. The researchers traced this difference to abnormal activity of BRG1, a protein that regulates how DNA is packaged and read.

BRG1 is a chromatin remodeler, meaning that it helps rearrange the structure of chromatin—the complex of DNA and proteins inside the nucleus. By repositioning nucleosomes, the compact units around which DNA is wrapped, chromatin remodelers can make particular genes more or less accessible to the transcriptional machinery. This gives them broad influence over cellular behavior. In mantle cell lymphoma, BRG1 is frequently mutated or otherwise dysregulated in tumors that no longer respond to BTK inhibitors.

The researchers found that aberrant BRG1 rewires gene expression in a way that suppresses ferroptosis. Its activity reduces the cellular conditions required for the death process, including the accumulation of reactive oxygen and free iron. In effect, BRG1 acts as a protective shield: while BTK inhibition places the lymphoma cell under stress, BRG1 strengthens the cell’s ability to neutralize oxidative damage before it can spread through the membrane.

This finding helps explain why simply continuing BTK inhibitor treatment may fail even when the drug remains capable of blocking its original molecular target. Resistance does not necessarily arise because the lymphoma cell restores BTK signaling. Instead, the cell can bypass the lethal consequences of BTK inhibition by changing its metabolism and antioxidant defenses. BRG1 therefore represents a vulnerability downstream of the drug’s primary target, one that may be exploitable even after the cancer has stopped responding to BTK therapy.

In laboratory experiments and animal models, combining a BRG1 inhibitor with a BTK inhibitor substantially increased antitumor activity compared with BTK inhibition alone. The combination also extended survival in treated animals. These results provide early evidence for a therapeutic strategy in which the cancer’s antioxidant protection is dismantled while BTK signaling is simultaneously suppressed. The approach could potentially be relevant beyond mantle cell lymphoma, although its safety and effectiveness in people will require clinical testing.

The study also highlights the growing importance of ferroptosis in cancer biology. Unlike apoptosis, the best-known form of programmed cell death, ferroptosis is governed by iron handling, lipid metabolism and cellular redox balance. Because malignant cells frequently divide rapidly and remodel their membranes at high rates, they may carry a biochemical weakness that can be exposed by targeted therapies. The Weill Cornell findings suggest that understanding which tumors retain or suppress this weakness could help guide treatment decisions and reveal combination therapies for patients whose cancers have become resistant.

Web References: https://www.nature.com/articles/s41467-026-75123-4

References: Nature Communications study published 2 July 2026; Weill Cornell Medicine investigators Dr. Soo-Yeon Hwang, Dr. Jihye Paik and Dr. Hongwu Zheng.

Keywords: Mantle cell lymphoma, BTK inhibitors, Bruton’s tyrosine kinase, BRG1, ferroptosis, oxidative stress, cancer drug resistance, B lymphocytes, chromatin remodeling, targeted therapy

Researchers employed cutting-edge whole-genome sequencing to explore the relationship between bacterial genetic variation and antimicrobial tolerance. By analyzing an extensive dataset of 1.3 million M. abscessus unitigs, which are sequence fragments capturing diverse genomic variations, the team mapped these to phenotypic profiles of drug resistance and tolerance. Using linear mixed models, which account for complex genetic relationships and environmental factors, they could carefully dissect the fraction of phenotypic variance attributable to genetic variance—a measure known as heritability.

The most striking revelation from their analysis was the high heritability of tolerance phenotypes across various antibiotics. Contrary to prior assumptions of tolerance being primarily a plastic, non-genetic feature, the data indicate that for many drugs, genetic determinants account for between 32% and an astonishing 97% of the variability in tolerance levels between isolates. This far exceeds the minimal 1.1% heritability expected by chance, underscoring the heritable and strain-specific nature of drug killing phenotypes.

The team further contrasted heritability estimates between drug resistance, measured as minimum inhibitory concentrations (MICs), and tolerance, assessed via the area under the killing curve (AUC), highlighting that while resistance to some antibiotics such as macrolides was strongly genetically determined, others like imipenem and cefoxitin showed low heritability. This likely reflects the interplay of drug chemical properties and biological variability affecting phenotypic measurements, providing critical insights into heterogeneity in resistance and tolerance mechanisms.

Beyond quantifying heritability, the researchers integrated these data with detailed phylogenetic analyses of over 350 M. abscessus isolates. This evolutionary perspective enabled them to characterize how tolerance traits have emerged and been conserved across bacterial lineages. Strikingly, both convergent evolution and clade-specific inheritance patterns were evident. For example, distinct high- or low-tolerance phenotypes have evolved independently multiple times—a phenomenon known as homoplasy—while other traits are inherited within closely related clades.

One particularly noteworthy finding was the identification of a low tigecycline tolerance clade nested within the dominant circulating clone of M. abscessus massiliense. This clade also harbors high-level mutational resistance to aminoglycosides and macrolides and is associated with increased virulence, highlighting a paradox where high genetic drug resistance coincides with vulnerabilities in drug tolerance. The low tolerance to tigecycline within this clade could represent an exploitable therapeutic weakness, offering new avenues to improve treatment outcomes for infections notoriously difficult to manage.

The implications of this study extend far beyond mere academic interest. Understanding that tolerance, like resistance, has a strong genetic basis challenges established dogma and opens new research pathways. Therapeutic strategies could be refined considering not only resistance profiles but also tolerance genotypes, enabling more precise combination therapies that prevent both survival and proliferation of pathogenic strains.

Equally remarkable is the study’s demonstration that large-scale phenotypic screens coupled with whole genome sequencing and sophisticated statistical modeling provide a powerful lens to map the complex genotype-phenotype landscape in microorganisms. This approach serves as a blueprint for dissecting genetic contributions to other complex traits in diverse infectious agents, potentially revolutionizing antimicrobial stewardship and drug development.

Moreover, the heterogeneity observed in both resistance and tolerance suggests that treatment failures and relapses in mycobacterial infections may stem as much from genetically encoded tolerance as from resistance mutations. Clinical microbiology diagnostics may need to incorporate tolerance assessments, enhancing predictive precision for therapeutic success and reducing the mounting burden of chronic infections.

This research also spotlights the nuanced relationships between genetic variation, bacterial physiology, and antimicrobial lethality, emphasizing that phenotypic assays alone cannot capture the full biology of tolerance. Comprehensively integrating high-resolution genotype data enables identification of subtle genetic variants controlling tolerance across populations, which could be missed by conventional methods.

By mapping killing phenotypes onto the bacterial phylogeny, the study reveals how evolutionary pressures shape drug response strategies in bacterial populations. These dynamics of clonal inheritance and repeated emergence of similar traits underscore evolutionary constraints and plasticity in antimicrobial survival mechanisms, encouraging deeper evolutionary-informed drug design.

Ultimately, this work represents a paradigm shift with wide-reaching consequences for clinicians, microbiologists, and pharmacologists. The discovery that drug tolerance is not simply a transient phenotypic state but is robustly genetically encoded gives actionable insight into combatting mycobacterial infections with higher lethality rates and poorer clinical outcomes. A refined understanding of the genetic landscape controlling tolerance holds promise for enhanced diagnostics, targeted therapeutics, and improved patient prognoses worldwide.

As multidrug-resistant infections continue to jeopardize global health, deciphering the genetic architecture of tolerance in pathogens like M. abscessus emerges as an urgent priority. This seminal study lays vital groundwork for future investigations and therapeutic innovations that can transform our ability to outmaneuver antimicrobials evasion.

Subject of Research: Genetic determinants of antimicrobial tolerance and resistance in Mycobacterium abscessus.

Article Title: Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.

Article References:
Jovanovic, A., Bright, F.K., Sadeghi, A. et al. Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes. Nat Microbiol (2026). https://doi.org/10.1038/s41564-025-02217-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41564-025-02217-y

CircRNA14781, a member of the burgeoning family of circular RNAs, exhibits intriguing regulatory capabilities that can influence gene expression. In this study, the authors illustrate how CircRNA14781 operates through the modulation of microRNA networks, specifically targeting miR-330-5p. This microRNA has been previously implicated in various cellular processes, including proliferation, apoptosis, and drug resistance. The relationship between CircRNA14781 and miR-330-5p is critical, as it reveals a novel regulatory axis that potentially alters the cellular response to chemotherapy.

One of the most striking findings of this research is the impact of CircRNA14781 on the expression of the nerve growth factor receptor, commonly referred to as NGFR. The study demonstrates that elevated levels of CircRNA14781 correlate with increased expression of NGFR, suggesting that this circular RNA acts as a sponge for miR-330-5p. This sponging mechanism effectively reduces the availability of miR-330-5p to target its mRNA sites, leading to enhanced NGFR expression. This axis of regulation clearly illustrates how non-coding RNAs can influence gene expression and contribute to therapeutic resistance.

The authors conducted comprehensive experiments to validate their hypotheses. Using ovarian cancer cell lines subjected to olaparib treatment, they observed a notable increase in CircRNA14781 expression in resistant cells compared to sensitive counterparts. Conversely, knocking down CircRNA14781 significantly restored sensitivity to olaparib, underscoring its functional role in mediating drug resistance. These findings highlight the potential of CircRNA14781 as a biomarker for therapy response, as well as a therapeutic target in resistant ovarian cancer.

The pathway involving miR-330-5p and NGFR is particularly important, as NGFR is known to play a pivotal role in cancer cell survival and proliferation. By boosting NGFR levels, CircRNA14781 may confer a survival advantage to ovarian cancer cells, allowing them to withstand the cytotoxic effects of olaparib. The study meticulously details the biochemical pathways involved, providing a robust framework for understanding how this circular RNA can disturb the balance between cell survival and death in the context of cancer treatment.

Moreover, the research offers compelling evidence for the potential therapeutic applications of targeting CircRNA14781. By designing agents that can inhibit the action of CircRNA14781, it might be possible to re-sensitize ovarian cancer cells to olaparib and other agents used in clinical oncology. These findings open avenues for innovative treatment strategies that could significantly improve patient outcomes and offer hope where traditional approaches fail.

One of the crucial aspects of this research lies in its contribution to the broader understanding of circular RNAs in cancer biology. The study builds upon existing literature that has highlighted the multifaceted roles of these non-coding RNAs in various malignancies. As the understanding of circRNAs deepens, it is becoming increasingly clear that these molecules are not merely byproducts of gene expression but potent regulators that can influence cancer progression and treatment responses.

In the context of ovarian cancer, where treatment resistance is rampant and complicates clinical management, the identification of CircRNA14781 as a contributor to olaparib resistance is particularly timely. The research not only elucidates a novel mechanism of resistance but also emphasizes the need for continued exploration into the role of non-coding RNAs in cancer. As molecular biology advances, the identification of new therapeutic targets is critical, and studies like this underscore the potential of RNA-based therapies.

This research aligns with ongoing efforts in cancer therapeutics to personalize treatment strategies. By understanding the molecular intricacies of drug resistance mechanisms, clinicians can tailor interventions that circumvent these barriers, potentially leading to more effective outcomes for patients. The implications of CircRNA14781 extend beyond the laboratory, promising to impact clinical approaches to treating ovarian cancer and perhaps other malignancies influenced by similar mechanisms of resistance.

As this field of study evolves, continuous efforts will be required to translate these findings from bench to bedside. The challenges of implementing new therapies based on RNA modulation must be addressed thoughtfully, considering factors like delivery mechanisms, safety, and efficacy. Nonetheless, the preliminary findings surrounding CircRNA14781 offer a hopeful glimpse into the future of cancer therapy, where understanding the molecular underpinnings of resistance can lead to revolutionary changes in treatment paradigms.

In conclusion, the research led by Chen et al. underscores the significance of understanding circular RNAs in the context of ovarian cancer and drug resistance. The study’s findings not only highlight a previously unrecognized player in olaparib resistance but also set the stage for future investigations that could yield transformative therapies. As the scientific community continues to unravel the complexities of cancer biology, the potential for circular RNAs like CircRNA14781 to contribute to meaningful advancements in treatment remains a promising area of exploration.

Advancements in cancer research, such as those presented here, are vital as we strive for precision oncology—a future where therapies are tailored to the individual molecular profile of a patient’s tumor. Such personalized medicine holds the key to improving survival rates and quality of life for patients battling cancer, particularly in aggressive forms like ovarian cancer. As researchers build upon the findings of CircRNA14781 and its role in drug resistance, the hope is for a future in which no patient has to face the devastating impact of treatment-resistant cancer.

In summary, this study not only sheds light on the mechanisms of drug resistance in ovarian cancer but also signifies a shift in how we approach cancer treatment. By integrating knowledge from molecular biology and therapeutic discovery, we can foresee a landscape where treatment is not just about killing cancer cells but also about understanding the intricate dance of regulatory networks that govern their behavior. The journey toward effective cancer therapies is long and arduous, but with every discovery, we move closer to conquering this formidable disease.

Subject of Research: CircRNA14781 and its role in olaparib resistance in ovarian cancer cells.

Article Title: CircRNA14781 promotes olaparib resistance of ovarian cancer cells by regulating miR-330-5p/NGFR pathway.

Article References:

Chen, B., Zong, S., Tang, J. et al. CircRNA14781 promotes olaparib resistance of ovarian cancer cells by regulating miR-330-5p/NGFR pathway. J Ovarian Res (2026). https://doi.org/10.1186/s13048-025-01957-z

Image Credits: AI Generated

DOI:

Keywords: CircRNA, olaparib resistance, ovarian cancer, miR-330-5p, NGFR, non-coding RNA, cancer biology, drug resistance, therapeutic target.

Nucleotide metabolism lies at the heart of cellular function, fueling DNA and RNA synthesis essential for cell proliferation and survival. The complex interplay of enzymes that govern nucleotide pools has long been a subject of intense investigation. Now, Strefeler and colleagues have shed light on the underappreciated contribution of NUDT5, an enzyme traditionally linked to metabolite homeostasis, in modulating the availability of phosphoribosyl pyrophosphate (PRPP), a pivotal substrate for nucleotide biosynthesis.

The study begins by exploring how deletion of the NUDT5 gene influences nucleotide balance within cells. Using cutting-edge metabolomic profiling in engineered knockout (KO) cell lines, the team detected a striking perturbation in intracellular PRPP levels. Given PRPP’s central role as a donor of ribose-phosphate groups in the salvage and de novo synthesis pathways of nucleotides, such disruption has profound implications for nucleotide metabolism dynamics and cellular fitness.

Delving deeper, the authors investigated the functional consequences of disrupted nucleotide pools on the efficacy of nucleobase analogues—therapeutic agents structurally mimicking natural bases that require activation through PRPP-dependent pathways. These agents, widely used in chemotherapy, rely on cellular metabolic processes to be converted into cytotoxic nucleotides. Interestingly, cells deficient in NUDT5 demonstrated a remarkable resistance to 5-fluorouracil (5-FU), a cornerstone pyrimidine analogue in cancer therapy, exhibiting an order of magnitude higher IC50 compared to wild-type controls.

This resistance appears intimately linked to the metabolic activation routes of these drugs. 5-FU requires phosphorylation and conversion steps ultimately dependent on PRPP availability, predominantly mediated by enzymes like thymidine phosphorylase (TYMP) and uridine monophosphate synthetase (UMPS). In contrast, analogues such as 5-fluorouridine, a nucleoside form bypassing PRPP requirement, retained unaltered efficacy in NUDT5 knockout cells. This differential sensitivity underscores the specificity of NUDT5’s impact on PRPP-dependent metabolism.

Expanding the scope, the research team tested an array of clinically relevant purine and pyrimidine analogues. Consistently, nucleobase analogues that depend on PRPP activation manifested reduced cytotoxicity in NUDT5-deficient cells, irrespective of their purine or pyrimidine nature. Conversely, sensitivity to nucleotide and nucleoside analogues, which bypass PRPP-utilizing activation mechanisms, remained unaffected. These results suggest a broad and specific modulatory role for NUDT5 in nucleobase analogue metabolism and therapeutic response.

Unexpectedly, these findings offer a mechanistic explanation to previously ambiguous observations from high-throughput genetic screens that implicated NUDT5 in resistance to the purine analogue 6-thioguanine, though detailed pathways were not elucidated. By bridging metabolomic data with functional resistance profiles, this work provides a coherent framework linking NUDT5 activity to chemotherapeutic susceptibility patterns.

The researchers further validated their findings using data from the Cancer Cell Line Encyclopedia (CCLE), confirming that the relationship between NUDT5 expression and nucleobase analogue resistance transcends specific cell lines and may represent a generalizable phenomenon in diverse cancer types. Such consistency accentuates the potential clinical relevance, raising the prospect that NUDT5 expression or activity could serve as a predictive biomarker for chemotherapy outcomes.

At a mechanistic level, the authors propose that NUDT5 modulates cellular PRPP pools by controlling fluxes in nucleotide degradation and salvage pathways, thereby fine-tuning the intracellular nucleotide landscape. This regulatory role situates NUDT5 as a critical enzyme at the crossroads of metabolism and drug response, influencing both nucleotide availability and the biotransformation efficiency of nucleobase analogues.

Intriguingly, the modulation of PRPP pools by NUDT5 may also impact broader metabolic processes beyond nucleotide synthesis. Since PRPP is a substrate shared by multiple biosynthetic pathways, including NAD+ and histidine synthesis, the enzyme’s activity potentially orchestrates complex metabolic cross-talk, a hypothesis inviting further exploration.

Moreover, the differential sensitivity of nucleobase versus nucleoside analogues to NUDT5 status suggests that therapeutic strategies modifying PRPP metabolism could be exploited to overcome drug resistance. For example, combining nucleobase analogues with agents that restore or mimic NUDT5 function might sensitize resistant tumors, enhancing chemotherapy efficacy.

This work also raises important questions regarding metabolic plasticity in cancer. The ability of cancer cells to adapt nucleotide biosynthesis routes and circumvent metabolic bottlenecks, such as those imposed by reduced NUDT5 function, illustrates the dynamic nature of metabolic rewiring in tumor evolution and therapy resistance.

From a translational perspective, targeting NUDT5 or its downstream metabolic effects emerges as a compelling avenue. Small molecule modulators of NUDT5 could either potentiate nucleobase analogue activation in resistant tumors or mitigate toxicities in normal tissues by adjusting nucleotide pools—a dual therapeutic potential that warrants rapid preclinical investigation.

Furthermore, these findings might inspire the design of novel nucleobase analogues structurally engineered to bypass PRPP dependence, offering alternative therapies for patients harboring metabolic adaptations impeding conventional nucleobase analogue activation.

On a broader scale, this study exemplifies the power of integrating metabolomic screening with functional genomics to decode complex resistance mechanisms, underscoring the necessity of multi-disciplinary approaches in modern cancer research.

The discovery of NUDT5’s role in PRPP regulation and nucleobase analogue sensitivity opens a new chapter in our understanding of nucleotide metabolism in oncogenesis and treatment response. As clinicians grapple with chemoresistance, insights like these pave the way for precision medicine strategies that tailor therapy based on tumor metabolic profiles.

In conclusion, Strefeler et al. deliver a compelling narrative linking metabolic enzyme function to chemotherapy resistance, highlighting NUDT5 as a pivotal regulator of nucleotide metabolism and a potential target for enhancing cancer treatment outcomes. Their work promises to catalyze further investigations into metabolic modifiers of drug sensitivity and heralds a new paradigm in the rational design of cancer therapeutics.

Subject of Research: Regulation of nucleotide synthesis and chemotherapeutic resistance mediated by NUDT5 enzyme activity.

Article Title: Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis.

Article References:
Strefeler, A., Baker, Z.N., Chollet, S. et al. Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01419-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01419-2

KRAS mutations are notorious drivers in approximately 30% of all human cancers, with an overwhelming 90% incidence in pancreatic ductal adenocarcinoma (PDAC), a malignancy characterized by dismal prognosis and limited treatment options. KRAS inhibitors have been hailed as potential game-changers, yet their clinical efficacy is frequently undermined by acquired drug resistance. This research addresses a critical gap: the role of metabolic rewiring and mitochondrial quality control, particularly mitophagy, in mediating resistance to KRAS-targeted therapies.

The study centers on the observation that KRAS inhibitors, specifically MRTX1133 targeting the KRAS(G12D) mutant and the pan-RAS inhibitor RMC-6236, lead to a significant reduction in ATP citrate lyase (ACLY) expression and consequently decrease cytosolic AcCoA levels in both murine KPC cells and human PDAC AsPC-1 cells harboring KRAS(G12D) mutations. This metabolic suppression initiates a cascade culminating in elevated mitophagy, a selective autophagic process for mitochondrial turnover. Importantly, the induction of mitophagy by KRAS inhibition was effectively antagonized by exogenous acetate supplementation, underscoring the centrality of the ACLY-AcCoA axis in controlling this process.

Delving deeper, the researchers demonstrated that mitophagy triggered by KRASi is strikingly dependent on NLRX1, a mitochondrial NOD-like receptor previously implicated in innate immune signaling and mitochondrial homeostasis. NLRX1-deficient cells exhibited a near-complete abrogation of KRASi-induced mitophagy, illuminating its indispensable role as a mediator of mitochondrial quality control in this context. The absence of NLRX1 not only hindered mitophagy but also resulted in pronounced accumulation of reactive oxygen species (ROS) and heightened cellular oxidative stress, as evidenced by increased NADP⁺/NADPH ratios.

The functional consequences of these molecular events were profound. NLRX1 deficiency sensitized cancer cells to KRAS inhibition, augmenting cytotoxicity in both murine and human KRAS-mutant PDAC and lung cancer models. This finding was further bolstered by experiments involving the antioxidant N-acetyl-L-cysteine (NAC), which rescued the viability of NLRX1-deficient cells exposed to KRASi by mitigating oxidative stress. It became evident that the mitophagy pathway represents a cellular defensive maneuver that mitigates ROS-induced damage to sustain tumor cell survival during KRAS-targeted therapy.

Complementing the in vitro analyses, in vivo studies employing a subcutaneous KPC tumor model in NSG mice cemented the therapeutic relevance of the ACLY–AcCoA–NLRX1 axis. Mice receiving the KRAS inhibitor MRTX1133 exhibited notable tumor regression, an effect amplified in the absence of NLRX1. Moreover, immunoblot and histological analyses revealed that while Acly suppression occurred uniformly across conditions, mitochondrial protein levels—indicative of mitophagy—were preserved in NLRX1-deficient tumors, affirming the disrupted mitophagic response. Consistently, ROS levels were reduced in control tumors following KRASi but escalated in NLRX1-lacking specimens, reinforcing the interplay between mitophagy, redox balance, and therapy resistance.

These revelations shift the paradigm by identifying mitophagy not merely as a housekeeping process but as a vital resistance mechanism exploited by cancer cells under pharmacologic assault. The study’s insights suggest that targeting the metabolic regulation of mitophagy—specifically through the ACLY-AcCoA-NLRX1 signaling axis—may enhance the efficacy of KRAS inhibitors and suppress tumor adaptation.

Intriguingly, this research also reports synergistic antitumor effects when combining KRAS inhibitors with mitophagy inhibitors like Mdivi-1, which exacerbates mitochondrial dysfunction and oxidative stress in cancer cells. This dual targeting strategy presents a compelling therapeutic avenue, potentially circumventing the resilience conferred by mitophagy-mediated mitochondrial clearance.

From a mechanistic viewpoint, the intimate connection between decreased ACLY activity and mitophagy induction underscores the broader concept that metabolic state functions as a signaling nexus. Cytosolic AcCoA emerges as more than a metabolic intermediate; it acts as a signaling metabolite communicating cellular energy and nutrient status to the mitophagy machinery. This axis elegantly illustrates how metabolic rewiring can intersect with organelle quality control to govern cell fate decisions during oncogenic stress.

Beyond immediate therapeutic implications, these findings raise significant questions about mitophagy’s role across diverse KRAS-mutant tumor types and contexts of therapy resistance. As chronic KRAS inhibition becomes more prevalent in clinical oncology, understanding how tumor cells engage mitochondrial quality control pathways could guide the design of combinatorial regimens that preempt or reverse resistance.

Moreover, this study highlights the vital importance of ROS homeostasis in malignancies driven by KRAS mutations. The intricate balance between mitochondrial removal and redox signaling revealed here may represent a universal vulnerability exploitable across cancers characterized by oxidative stress adaptations.

In conclusion, the elucidation of the ACLY–AcCoA–NLRX1 axis as a regulator of mitophagy in KRAS inhibitor-mediated drug resistance broadens the framework of cancer metabolism and organelle dynamics in oncogenesis. It opens exciting pathways for innovative treatments that disrupt tumor adaptive mechanisms, potentially transforming outcomes for patients afflicted with some of the deadliest KRAS-driven cancers.

Subject of Research:
KRAS-mutant cancer metabolism, mitophagy, and drug resistance mechanisms

Article Title:
Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy

Article References:
Zhang, Y., Shen, X., Shen, Y. et al. Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy. Nature (2025). https://doi.org/10.1038/s41586-025-09745-x

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41586-025-09745-x

Blastocystis spp., a genus of single-celled intestinal parasites, are among the most commonly identified protists in human stool samples worldwide. Their presence is often associated with a spectrum of gastrointestinal disturbances, ranging from asymptomatic colonization to irritable bowel syndrome-like manifestations and chronic diarrhea. However, the ambiguous pathogenic status of Blastocystis has historically hindered the development of standardized treatment regimens. This review systematically evaluates the antiparasitic pharmacotherapies aimed at eradicating Blastocystis, emphasizing therapeutic outcomes, drug resistance mechanisms, and potential adverse effects.

The study embarks on an exhaustive interrogation of the current arsenal of antiparasitic agents, most notably nitroimidazoles, such as metronidazole and ornidazole, which have traditionally been the cornerstone of treatment protocols. Their mode of action involves the disruption of DNA synthesis within the parasite, leading to cell death. However, accumulating evidence reveals inconsistent eradication rates and emerging resistance phenomena that cloud their long-term effectiveness, necessitating a critical reassessment of their standing in clinical practice.

Focusing closely on metronidazole, the most widely prescribed agent, the review unveils considerable variability in treatment success, contingent on dosage, duration, and Blastocystis subtype. This heterogeneity underscores the parasite’s biological diversity and its influence on pharmacodynamics. The authors argue that conventional one-size-fits-all approaches may inadvertently foster suboptimal responses and facilitate resistance, urging for subtype-targeted therapeutic strategies bolstered by molecular diagnostic advancements.

Expanding beyond metronidazole, the systematic survey explores the therapeutic potential of alternative drugs, including nitazoxanide, paromomycin, and trimethoprim-sulfamethoxazole. Nitazoxanide emerges as a promising candidate due to its broad-spectrum antiparasitic activity and favorable side effect profile. Yet, clinical trials remain sparse, and its mechanistic action against Blastocystis warrants deeper biochemical elucidation to optimize dosing schemas and mitigate resistance development.

The review also delves into the complex interplay between Blastocystis and the host’s gut microbiome, postulating that microbial ecology may significantly modulate treatment outcomes. Dysbiosis induced by certain antiparasitic agents could inadvertently perpetuate symptoms or facilitate recolonization, posing a paradoxical scenario that demands integrative therapeutic approaches combining microbiome modulation with targeted anti-Blastocystis strategies.

Another pivotal aspect addressed is the diagnostic challenge that hinders timely and accurate detection of Blastocystis infections. Conventional microscopy often falls short due to morphological similarities with non-pathogenic flora, leading to underdiagnosis or misinterpretation. The authors advocate for the adoption of advanced molecular diagnostics, such as PCR-based assays, which not only enhance sensitivity and specificity but also enable subtype differentiation critical for precision therapy.

Moreover, the review highlights the dire need for robust clinical trials to establish evidence-based treatment algorithms. The current literature is predominantly composed of small-scale studies with heterogeneous methodologies, limiting the generalizability of findings. Rigorous randomized controlled trials incorporating standardized outcome measures are indispensable to validate efficacy and safety profiles across diverse populations and Blastocystis variants.

An intriguing dimension explored is the potential immunomodulatory role of Blastocystis on the host. Some studies suggest certain subtypes may exert beneficial effects, fostering immune tolerance and gut homeostasis. This dualistic nature complicates the decision matrix surrounding eradication, calling for nuanced clinical judgment to balance parasite clearance against the preservation of symbiotic microbial functions.

In the realm of public health, the review underscores the epidemiological significance of Blastocystis, especially in low-resource settings where parasitic infections burden vulnerable populations. Enhanced surveillance, coupled with tailored antiparasitic interventions, could mitigate morbidity while addressing emerging resistance trends. The authors emphasize the integration of parasitological management within broader health frameworks to optimize resource allocation and impact.

Technological innovations, including high-throughput sequencing and metabolomics, offer promising avenues for unraveling Blastocystis biology and host interactions. These methodologies may illuminate novel drug targets and biomarkers predictive of treatment response, propelling personalized medicine approaches in parasitology. The review anticipates that multidisciplinary collaborations will accelerate these breakthroughs, fostering translational applications.

Furthermore, the authors reflect on the socio-economic ramifications of Blastocystis infections, noting the often-overlooked productivity losses and healthcare expenditures attributed to subclinical and chronic cases. By refining therapeutic strategies and enhancing diagnostic acumen, the medical community can alleviate the silent burden imposed by this parasite, improving patient quality of life and economic outcomes.

In conclusion, this comprehensive systematic review provides a critical appraisal of antiparasitic efficacy against Blastocystis species, spotlighting the pressing need for precision therapeutics and enhanced diagnostic infrastructure. As resistance profiles evolve and microbiome insights deepen, tailored interventions that consider parasite heterogeneity, host factors, and ecological dynamics will be paramount. This work lays a foundational platform guiding future research endeavors and clinical practice, catalyzing progress in the quest to effectively manage Blastocystis-associated diseases.

The scientific community now stands at a crossroads, equipped with emerging tools yet grappling with complex biological conundrums posed by Blastocystis. The journey toward optimized antiparasitic regimens is poised to redefine paradigms in gastrointestinal parasitology, promising to transform patient outcomes and public health strategies worldwide.

Subject of Research: Efficacy of antiparasitic agents in treating Blastocystis species

Article Title: A Systematic Review about the Efficacy of Antiparasitic Agents in the Treatment of Blastocystis Species

Article References:
Ulusan Bağcı, Ö., Aral Akarsu, G. A Systematic Review about the Efficacy of Antiparasitic Agents in the Treatment of Blastocystis Species. Acta Parasit. 70, 208 (2025). https://doi.org/10.1007/s11686-025-01145-5

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11686-025-01145-5

One of the primary challenges posed by CAFs lies in their ability to generate a dense and complex ECM that severely impairs the penetration of therapeutic agents. While the enhanced permeability and retention (EPR) effect has been the cornerstone rationale for nanoparticle-based drug delivery—relying on the leaky vasculature of tumors—the excessive ECM produced by CAFs forms a formidable barrier. This barrier restricts the ability of nanoparticles, especially those around 100 nm in diameter commonly used in clinical formulations, from diffusing deep into tumor cores. Evidence suggests that only nanoparticles smaller than 30 nm can navigate through such dense matrices to reach the interior cancer cells, revealing a critical size-dependent limitation that challenges current drug delivery designs.

Moreover, the ECM created by CAFs restricts the infiltration of cytotoxic immune cells, particularly T lymphocytes, into the tumor mass. The T-cell migration mechanism known as ameboid movement depends on a loosely organized network of ECM fibers. When CAFs promote a high-density, fine-lattice ECM scaffold, this physical barrier impedes T cells’ mobility, preventing them from penetrating tumors effectively. This spatial exclusion of T cells from tumor interiors is a significant hurdle in immunotherapies, such as checkpoint inhibitors, where successful anti-tumor immune responses require direct contact between immune effector cells and cancer cells. The enhanced interstitial fluid pressure caused by this ECM also inhibits immune cell extravasation from blood vessels.

Beyond serving as a physical barricade, ECM components actively suppress immune functions through receptor-mediated signaling pathways. Collagen, a major ECM protein secreted by CAFs, interacts with leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) on T cells and natural killer (NK) cells. This interaction triggers inhibitory signals that dampen the cytotoxic activity of immune cells, contributing to the tumor’s immune evasion. Similarly, fibronectin engagement with leukocyte immunoglobulin-like receptor B4 (LILRB4) further enforces immunosuppression within the TME. These insights reveal how CAF-engineered ECM not only blocks cellular infiltration but also actively modulates immune cell functionality.

Another crucial role of the ECM is acting as a reservoir and regulator for growth factors fundamental to tumor progression. Transforming growth factor-beta (TGF-β), a well-known driver of fibrosis and cancer cell plasticity, remains stored in the ECM in a latent form, sequestered by a complex of peptides and ECM proteins. ECM degradation, often mediated by matrix metalloproteinases (MMPs) secreted by CAFs, releases active TGF-β, modulating the behavior of both cancer cells and surrounding stromal cells. Moreover, the mechanical properties of the ECM, such as its stiffness, can influence cancer cell fate decisions. For example, increased ECM stiffness in breast cancer is correlated with enhanced stemness and plasticity of tumor cells, while excessive rigidity paradoxically induces dormancy, creating niches for cancer relapse.

The involvement of CAFs extends beyond the primary tumor site to the promotion of metastasis, the spread of cancer cells to distant organs. One of the well-characterized mechanisms involves the induction of epithelial-mesenchymal transition (EMT), a phenotypic switch where epithelial cancer cells acquire mesenchymal traits, enhancing their migratory and invasive abilities. CAFs secrete a variety of cytokines—including tumor necrosis factor-alpha (TNF-α), interleukins such as IL-6 and IL-1β, and TGF-β—which orchestrate the EMT process. Notably, inflammatory CAFs (iCAFs) secrete IL-6, which has been shown to potentiate EMT in human bladder cancer cells, further endorsing the role of CAFs in promoting cancer cell plasticity and metastasis.

In parallel, CAFs actively remodel the ECM by secreting MMPs that degrade and reorganize matrix proteins. This remodeling creates “tracks” or channels within the ECM, facilitating cancer cell migration. Experimental data from co-culture studies show that CAFs infiltrate collagen gels matrix first, carving pathways that cancer cells subsequently follow, highlighting the cooperative invasion strategy. Interestingly, cancer stem cells exhibit enhanced migratory capacity in the presence of CAFs compared to non-stem cancer cells, suggesting that CAFs selectively foster the metastatic potential of more aggressive tumor cell subpopulations.

The ECM dynamics and stiffness modulated by CAF activity also influence tumor cell behavior and therapeutic response. In colorectal cancer liver metastases, for example, the mechanical forces exerted by ECM stimulate hepatic stellate cells to release free fatty acids, which are then utilized by cancer cells via fatty acid oxidation pathways to gain resistance against therapy. This metabolic crosstalk underscores the multifaceted interactions between stroma and cancer cells, positioning ECM not just as a scaffold but as an active metabolic influencer sustaining tumor survival.

With the recognition of CAFs as central architects of the tumor microenvironment and contributors to treatment resistance, therapeutic strategies targeting CAFs have gained momentum. Three primary approaches dominate current research: first is the inhibition of CAF activation or their secreted cytokines, focusing on signaling pathways that maintain CAF phenotype; second is the physical elimination of CAFs, using techniques such as chimeric antigen receptor (CAR) T-cell therapies directed against fibroblast activation protein (FAP) or antibodies that target CAF-specific antigens; third is the normalization of CAFs, wherein activated fibroblasts are reprogrammed into their resting state (rCAFs) through agents like pirfenidone or vitamin derivatives, thereby restoring a less fibrotic, more treatment-permissive microenvironment.

These strategies face challenges, notably the heterogeneity of CAF populations within tumors, which include myofibroblastic CAFs that produce excessive ECM, inflammatory CAFs that modulate immune responses, and antigen-presenting CAFs that foster immunosuppressive T regulatory cell formation. The multifaceted nature of CAFs requires nuanced therapeutic designs that can selectively modulate pathological CAF subtypes without disrupting normal fibroblast function in healthy tissue. Nonetheless, preclinical models show promising results, where CAF elimination or normalization leads to enhanced infiltration of immune cells and improved drug delivery.

The dense ECM scaffold produced by CAFs thus represents a double-edged sword; while it supports tumor growth and survival, it also presents an obstacle to effective treatment. Innovative nanomedicine designs are now exploring ultrasmall nanoparticles and ECM-degrading enzymes to improve therapeutic penetration. Simultaneously, combination therapies pairing CAF-targeting agents with immunotherapies or conventional chemotherapies are gaining traction, aiming to synergistically dismantle the protective stromal niche.

Importantly, the mechanobiology of tumors, influenced heavily by ECM stiffness, is garnering increasing attention in cancer research. By mechanically modulating the tumor landscape, CAFs influence not only the physical migration of cancer cells but also their phenotypic plasticity and metabolic state. These biomechanical cues represent new frontiers in understanding tumor heterogeneity and resistance mechanisms.

In conclusion, CAFs constitute a critical non-malignant cell population that profoundly remodels the tumor microenvironment through ECM production, immune suppression, and biochemical signaling. This tripartite influence drives therapeutic resistance and enhances cancer invasiveness, underscoring the urgent need for therapies that can modulate their activity. Future advancements in CAF-targeted therapies hold promise to overcome resistance barriers, improve drug delivery, and ultimately enhance patient outcomes in difficult-to-treat cancers such as pancreatic ductal adenocarcinoma and breast cancer.

Subject of Research: Cancer-associated fibroblasts and their roles in cancer progression, metastasis, and therapy resistance.

Article Title: Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review.

Article References:
Masuda, H. Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review. Cell Death Discov. 11, 341 (2025). https://doi.org/10.1038/s41420-025-02566-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02566-x